• Explore /
  • Poster
  • / Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.

Abstract Poster

Authors

null

Marianne E. Pavel

Charité Berlin Campus Virchow-Klinikum, Berlin, Germany

Marianne E. Pavel , Catherine Lombard-Bohas , Eric Van Cutsem , Du Hung Lam , Tiffany Kunz , Ulrike Brandt , Jaume Capdevila , Elisabeth De Vries , Paola Tomassetti , Timothy J. Hobday , Rodney F. Pommier , James C. Yao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT00510068

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4091)

DOI

10.1200/jco.2015.33.15_suppl.4091

Abstract #

4091

Poster Bd #

201

Abstract Disclosures

Similar Posters

First Author: Manisha Shah

First Author: Francis Arena

First Author: Jonathan Strosberg

First Author: Elisabeth De Vries